curasan AG Received Licence for ATR(R)

Kleinostheim, Germany, 16 October 2009 – curasan AG, which is listed on the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has been received CE certification and, therefore, marketing authorization for the ATR® (Advanced Tissue Regeneration) product.

ATR® is a disposable system that is used to enrich the body’s own growth factors to a level many times higher than normal blood values. The most important areas of application are serious skin damage, such as decubitus and ulcers, large area burns, skin transplants, plastic surgery and the optimised regeneration of bone and mucous tissue. A crucial advantage of the product is that it is a disposable system. This means that, in contrast to PRP (platelet rich plasma), it can be used without the aid of centrifuges and thereby saves the user expensive capital goods. Furthermore, a much higher concentration of growth factors that are free from superfluous accompanying substances is achieved.

The issuing of the certification means that preparations for full scale production can begin and ATR® is now scheduled to be ready for distribution early 2010.

“We now have the perfect basis from which to conduct successful negotiations for the awarding of distribution licences,” comments Hans Dieter Rössler, CEO of curasan AG. “Our aim is to co-operate with various distribution partners that can already demonstrate optimal positioning in their particular markets and segments.”

The documentation required for the ATR® distribution approval in the USA will be prepared by the end of the year for submission to the responsible authority, the FDA (Federal Drug Administration).

Background information about curasan AG:

Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.

Back to news